NAGE — Niagen Bioscience, Inc.
—
Nasdaq ·
Materials ·
Chemicals ·
CIK 1386570 ·
Last close
$3.39
Market Cap
$269.99M
52W High
$5.12
52W Low
$3.18
ADV30
743,444
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 31,474,000 | 19,976,000 | 1,576,000 | 6,318,000 | 114,329,000 | 66,397,000 | 31,999,000 |
| Dec 2025 | 33,839,000 | 21,704,000 | 2,103,000 | 4,132,000 | 106,406,000 | 64,636,000 | 29,873,000 |
| Sep 2025 | 33,986,000 | 21,928,000 | 4,236,000 | 4,578,000 | 98,139,000 | 64,138,000 | 27,463,000 |
| Jun 2025 | 31,117,000 | 20,226,000 | 3,185,000 | 3,609,000 | 91,525,000 | 60,322,000 | 27,330,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$13,504,000
Investing CF
$-292,000
Financing CF
$6,916,000
CapEx
$-292,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$0.20
As of
2026-05-10
Balance + Analyst (yfinance extras)
Retained Earnings
$-164,528,000
Inventory
$20,424,000
Receivables
$9,741,000
ST Investments
—
EBIT TTM
$14,296,000
Pretax Income TTM
$18,192,000
Interest Exp TTM
—
Analysts
5
Yahoo Snapshot (yfinance, live)
Total Revenue
$130,416,000
EBITDA
$11,981,000
Free Cash Flow
$-1,196,500
Enterprise Value
$214,720,528
Total Cash
$66,397,000
Total Debt
$2,576,000
Shares Out
79,644,327
Trailing EPS
$0.21
Book Value
$1.03
ROE
27.1%
ROA
7.1%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 129,423,000 | 14,296,000 | 17,382,000 | 106,406,000 | 29,873,000 | — | 13,504,000 |
| Dec 2024 | 99,597,000 | 7,726,000 | 8,550,000 | 68,278,000 | 22,184,000 | — | 12,109,000 |
| Dec 2023 | 83,570,000 | -5,599,000 | -4,938,000 | 54,964,000 | 26,508,000 | — | 7,117,000 |
| Dec 2022 | 72,050,000 | -18,628,000 | -16,540,000 | 54,057,000 | 25,385,000 | — | -15,098,000 |
TTM Snapshot
Revenues TTM
$25,580,000
NetIncome TTM
$1,878,000
OpCashFlow TTM
$0
Assets (Latest)
$68,278,000
Forward EPS
$0.32
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| CRLBF | Cresco Labs Inc. | $269.21M | $0.76 | — |
| LTBR | LIGHTBRIDGE Corp | $276.55M | $8.42 | — |
| NL | NL INDUSTRIES INC | $296.33M | $6.06 | — |
| YSG | Yatsen Holding Ltd | $230.87M | $3.62 | — |
| OEC | Orion S.A. | $320.85M | $5.69 | — |
News headlines (Yahoo Finance, 1h cache)
Niagen Bioscience CEO Rob Fried to Participate in Virtual Fireside Chat to Discuss Pharmaceutical Strategy on July 15, 2026
2026-07-09 12:32 · Yahoo
Niagen Bioscience Launches Pharmaceutical Program for Accelerated Aging and Rare Genetic Diseases
2026-07-08 12:32 · Yahoo
Implied Volatility Surging for Niagen Bioscience Stock Options
2026-07-06 15:15 · Yahoo
Niagen Bioscience Inc. (NAGE) Renames Research Program Amid Focus in Advancing NAD+ Applications
2026-06-19 18:20 · Yahoo
Niagen Bioscience (NAGE) Stock Sees Split Analyst Revisions As Price Targets Fall
2026-06-17 13:12 · Yahoo
Assessing Niagen Bioscience (NAGE) Valuation As It Renames Its NAD+ Research Program
2026-06-05 03:14 · Yahoo
Niagen Bioscience to Present at the 16th Annual East Coast IDEAS Investor Conference
2026-06-03 12:34 · Yahoo
How The Niagen Bioscience (NAGE) Investment Story Is Evolving Without New Analyst Signals
2026-06-02 15:10 · Yahoo
Niagen Bioscience Renames ChromaDex External Research Program to the Niagen Research Program, Strengthening Position as the Global Leader in NAD+ Science
2026-06-02 12:32 · Yahoo
3 Growth Companies With High Insider Ownership And 15% Revenue Growth
2026-05-22 11:35 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.